Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL 2018 treatment protocol for children and adolescents with lymphoblastic lymphoma
2023-508101-24-00Phase 3Authorised
- Sponsor
- Universitätsklinikum Münster
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of vincristine, mercaptopurine, methotrexate, daunorubicin, prednisolone and 9 more in lymphoblastic lymphoma (LL) (2 arms), sponsored by Universitätsklinikum Münster. Primary endpoints: Cumulative incidence of relapse with involvement of the central nervous system and Event-free survival. Planned start Aug 2019; status: authorised.
02
Drugs
vincristinemercaptopurinemethotrexatedaunorubicinprednisolone
03
Conditions
lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on 2023-508101-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508101-24-00.